You're Registered

You will shortly be receiving an automatic email confirming your online registration and within the next 24 hours, you will receive your invoice and/or payment confirmation.

If you have any questions about your registration, please contact:

We look forward to welcoming you to the conference.

Important Note - Fraudulent Accommodation Booking Scams

We have been made aware that there are third-party companies contacting our conference attendees claiming to represent Hanson Wade Group with fraudulent hotel booking schemes.

Hanson Wade Group does not work with any third parties and accommodation information will only come directly from your Event Manager. For your safety, please only book your accommodation through official links provided by Hanson Wade Group. Learn more in our full accommodation policy: Accommodation Policy - Hanson Wade Group.

Share Your Attendance

7th-Genome-Editing-Therapeutics-Summit-Attending-Banner (1)

Download the 'I'm Attending' banner to share your participation regarding the 7th Genome Editing Therapeutics Summit.

When posting, don't forget to tag our Cell & Gene Therapy Page on LinkedIn!

Feel free to use our sample text below if you need some inspiration:

With 2026 set to be a defining year for Genome Therapies and CRISPR Innovation, I am excited to attend the 7th Genome Editing Therapeutics Summit this September 28-30 in Boston.

As the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting, this year's meeting will bring together senior experts from Beam Therapeutics, Eli Lilly, Sanofi, Prime Medicine, Metagenomi, Scribe Therapeutics, Intellia, AbbVie, Arbor Biotechnologies, Epicrispr and more.

With an 80% Director, VP & C-Suite level audience, this summit is where senior decision-making and connections are being made.

Learn more about the summit and how to join here: https://ter.li/o3ycrcg6

Explore Related Products

Explore our range of related products designed to support your drug discovery and development journey.